Which has stronger valuation & earnings, TIL or NKTX?

Nkarta is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Nkarta N/A N/A -$104.08M -$1.34 N/A

Is TIL or NKTX more profitable?

Nkarta's return on equity of -30.90% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Nkarta N/A -30.90% -24.20%

Does the media favor TIL or NKTX?

In the previous week, Nkarta had 2 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Nkarta and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.60 beat Nkarta's score of 0.59 indicating that Instil Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Instil Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nkarta 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, TIL or IMUX?

Immunic is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Immunic N/A N/A -$97.17M -$5.58 N/A

Is TIL or IMUX more profitable?

Instil Bio's return on equity of -39.76% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Immunic N/A -220.75% -132.04%

Which has preferable earnings and valuation, TIL or NERV?

Instil Bio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A

Is TIL or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Minerva Neurosciences N/A N/A -32.63%

Does the media prefer TIL or VYGR?

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.60 beat Voyager Therapeutics' score of 0.67 indicating that Instil Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Instil Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Voyager Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KRRO or TIL more profitable?

Instil Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Instil Bio's return on equity of -39.76% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -117.86% -71.04% Instil Bio N/A -39.76% -22.38%

Instil Bio (TIL) Competitors

$7.25 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.28 +0.03 (+0.34%)

As of 04:10 PM Eastern

Compare

TIL vs. NKTX, IMUX, NERV, VYGR, and KRRO

Should you buy Instil Bio stock or one of its competitors? MarketBeat compares Instil Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Instil Bio include Nkarta (NKTX), Immunic (IMUX), Minerva Neurosciences (NERV), Voyager Therapeutics (VYGR), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry.

How does Instil Bio compare to Nkarta?

Instil Bio (NASDAQ:TIL) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Nkarta had 2 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Nkarta and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.60 beat Nkarta's score of 0.59 indicating that Instil Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Instil Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nkarta	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Instil Bio has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Nkarta has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Nkarta is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 80.5% of Nkarta shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 9.8% of Nkarta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 810.34%. Nkarta has a consensus target price of $10.75, suggesting a potential upside of 316.67%. Given Instil Bio's higher probable upside, equities research analysts plainly believe Instil Bio is more favorable than Nkarta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Nkarta's return on equity of -30.90% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Nkarta	N/A	-30.90%	-24.20%

Summary

Instil Bio and Nkarta tied by winning 7 of the 14 factors compared between the two stocks.

How does Instil Bio compare to Immunic?

Instil Bio (NASDAQ:TIL) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 5.5% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Immunic is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 810.34%. Immunic has a consensus price target of $47.57, indicating a potential upside of 214.00%. Given Instil Bio's higher possible upside, analysts clearly believe Instil Bio is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Instil Bio's return on equity of -39.76% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Immunic	N/A	-220.75%	-132.04%

In the previous week, Instil Bio had 1 more articles in the media than Immunic. MarketBeat recorded 1 mentions for Instil Bio and 0 mentions for Immunic. Instil Bio's average media sentiment score of 1.60 beat Immunic's score of 0.00 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Immunic	Neutral

Instil Bio has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Summary

Instil Bio beats Immunic on 10 of the 14 factors compared between the two stocks.

How does Instil Bio compare to Minerva Neurosciences?

Instil Bio (NASDAQ:TIL) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Instil Bio has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.16, indicating that its share price is 116% less volatile than the broader market.

In the previous week, Instil Bio had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 1 mentions for Instil Bio and 0 mentions for Minerva Neurosciences. Instil Bio's average media sentiment score of 1.60 beat Minerva Neurosciences' score of 0.00 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Minerva Neurosciences	Neutral

Minerva Neurosciences' return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Minerva Neurosciences	N/A	N/A	-32.63%

Instil Bio currently has a consensus target price of $66.00, indicating a potential upside of 810.34%. Minerva Neurosciences has a consensus target price of $10.50, indicating a potential upside of 134.38%. Given Instil Bio's higher possible upside, research analysts clearly believe Instil Bio is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Instil Bio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Summary

Instil Bio beats Minerva Neurosciences on 9 of the 13 factors compared between the two stocks.

How does Instil Bio compare to Voyager Therapeutics?

Instil Bio (NASDAQ:TIL) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Instil Bio has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Instil Bio's return on equity of -39.76% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Voyager Therapeutics	-319.61%	-55.97%	-43.12%

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Instil Bio has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Instil Bio currently has a consensus price target of $66.00, indicating a potential upside of 810.34%. Voyager Therapeutics has a consensus price target of $16.50, indicating a potential upside of 425.48%. Given Instil Bio's higher possible upside, equities research analysts plainly believe Instil Bio is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Instil Bio has higher earnings, but lower revenue than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Voyager Therapeutics	$40.37M	4.70	-$119.72M	-$1.97	N/A

In the previous week, Instil Bio and Instil Bio both had 1 articles in the media. Instil Bio's average media sentiment score of 1.60 beat Voyager Therapeutics' score of 0.67 indicating that Instil Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Instil Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Voyager Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Instil Bio beats Voyager Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Instil Bio compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Instil Bio has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Instil Bio's return on equity of -39.76% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
Instil Bio	N/A	-39.76%	-22.38%

Korro Bio currently has a consensus target price of $16.71, suggesting a potential upside of 39.75%. Instil Bio has a consensus target price of $66.00, suggesting a potential upside of 810.34%. Given Instil Bio's higher possible upside, analysts plainly believe Instil Bio is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Korro Bio has a beta of 3, suggesting that its stock price is 200% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

In the previous week, Instil Bio had 1 more articles in the media than Korro Bio. MarketBeat recorded 1 mentions for Instil Bio and 0 mentions for Korro Bio. Instil Bio's average media sentiment score of 1.60 beat Korro Bio's score of 0.00 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Korro Bio	Neutral
Instil Bio	Very Positive

Instil Bio has lower revenue, but higher earnings than Korro Bio. Korro Bio is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	26.99	-$117.26M	-$11.67	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Summary

Instil Bio beats Korro Bio on 11 of the 16 factors compared between the two stocks.

Get Instil Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TIL vs. The Competition

Export

Metric	Instil Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.17M	$3.66B	$6.82B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.02	20.80	27.00	24.20
Price / Sales	N/A	322.97	519.38	94.43
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.43	8.17	10.67	6.26
Net Income	-$71.37M	$23.81M	$3.60B	$331.76M
7 Day Performance	-7.29%	-1.12%	-0.32%	-1.10%
1 Month Performance	-3.33%	2.64%	1.88%	-1.26%
1 Year Performance	-73.75%	45.50%	25.50%	18.84%

Instil Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TIL Instil Bio	1.6538 of 5 stars	$7.25 flat	$66.00 +810.3%	-72.2%	$49.17M	N/A	N/A	410	Positive News
NKTX Nkarta	3.7539 of 5 stars	$2.65 -5.0%	$10.75 +305.7%	+34.6%	$199.61M	N/A	N/A	140
IMUX Immunic	2.6697 of 5 stars	$14.69 +0.3%	$47.57 +223.8%	+55.6%	$199.42M	N/A	N/A	70
NERV Minerva Neurosciences	1.7278 of 5 stars	$4.02 -5.9%	$10.50 +161.2%	+115.8%	$198.93M	N/A	N/A	9	Positive News
VYGR Voyager Therapeutics	3.1157 of 5 stars	$3.16 -2.5%	$16.50 +422.2%	-5.9%	$195.76M	$40.37M	N/A	100	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TIL) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Instil Bio (TIL) Competitors

TIL vs. NKTX, IMUX, NERV, VYGR, and KRRO

How does Instil Bio compare to Nkarta?

Summary

How does Instil Bio compare to Immunic?

Summary

How does Instil Bio compare to Minerva Neurosciences?

Summary

How does Instil Bio compare to Voyager Therapeutics?

Summary

How does Instil Bio compare to Korro Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Instil Bio (TIL) Competitors

TIL vs. NKTX, IMUX, NERV, VYGR, and KRRO

How does Instil Bio compare to Nkarta?

Does the media favor TIL or NKTX?

Which has more risk & volatility, TIL or NKTX?

Which has stronger valuation & earnings, TIL or NKTX?

Do insiders & institutionals hold more shares of TIL or NKTX?

Do analysts rate TIL or NKTX?

Is TIL or NKTX more profitable?

Summary

How does Instil Bio compare to Immunic?

Do insiders & institutionals have more ownership in TIL or IMUX?

Which has preferable earnings and valuation, TIL or IMUX?

Do analysts rate TIL or IMUX?

Is TIL or IMUX more profitable?

Does the media favor TIL or IMUX?

Which has more risk & volatility, TIL or IMUX?

Summary

How does Instil Bio compare to Minerva Neurosciences?

Which has more volatility & risk, TIL or NERV?

Does the media prefer TIL or NERV?

Is TIL or NERV more profitable?

Do analysts rate TIL or NERV?

Do insiders and institutionals believe in TIL or NERV?

Which has preferable earnings and valuation, TIL or NERV?

Summary

How does Instil Bio compare to Voyager Therapeutics?

Is TIL or VYGR more profitable?

Do institutionals & insiders believe in TIL or VYGR?

Which has more risk and volatility, TIL or VYGR?

Do analysts recommend TIL or VYGR?

Which has stronger valuation & earnings, TIL or VYGR?

Does the media prefer TIL or VYGR?

Summary

How does Instil Bio compare to Korro Bio?

Is KRRO or TIL more profitable?

Do analysts rate KRRO or TIL?

Do institutionals and insiders hold more shares of KRRO or TIL?

Which has more volatility & risk, KRRO or TIL?

Does the media prefer KRRO or TIL?

Which has stronger valuation and earnings, KRRO or TIL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TIL vs. The Competition

Instil Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools